ATIII


Also found in: Medical.
AcronymDefinition
ATIIIAntithrombin III (anticoagulant)
References in periodicals archive ?
The ATIII LLC joint venture was established by Genzyme Transgenics and Genzyme General for the development, marketing, and distribution of rhATIII in the United States and Europe.
Yesterday, Genzyme Transgenics and parent Genzyme General (Nasdaq: GENZ) announced that the FDA has granted Orphan Drug designation for their product recombinant human antithrombin III (rhATIII) for the treatment of ATIII dependent heparin resistant patients requiring anticoagulation.
Using photo-optical detection with a 405 nm halogen light source, the compact, benchtop analyzer performs many tests, including: PT, aPTT, TT, FIB (fibrinogen), factor assays, INR, ATIII, plasminogen, [alpha]-2 antiplasmin, heparin anti-Xa, protein C, APCR (activated protein C resistance), lupus screen and confirmatory, PNP, P+P, and mixing studies, as well as user-programmable tests such as clottable protein C and S.
Nasdaq: GZTC) and Genzyme General (Nasdaq: GENZ) today announced that the United States Food and Drug Administration has granted Orphan Drug designation for their product recombinant human antithrombin III (rhATIII) for the treatment of ATIII dependent heparin resistant patients requiring anticoagulation.
Secondary endpoints included maintenance of normal ATIII levels and changes in two biochemical markers of coagulation: D-dimer and fibrin monomer.
In conjunction with the Science publication, Genzyme Molecular Oncology also announced a planned collaboration with the ATIII LLC to develop aaATIII as a potential cancer treatment.
Development of aaATIII is the basis of a planned collaboration between Genzyme Molecular Oncology and the ATIII LLC, the joint venture between Genzyme Transgenics (Nasdaq: GZTC) and Genzyme General (Nasdaq: GENZ), (see companion press release).
16 /PRNewswire/ -- Genzyme Molecular Oncology (Nasdaq: GZMO) and the ATIII LLC, a joint venture between Genzyme Transgenics Corp.
ATIII is a protein normally found in human plasma that helps regulate blood clotting.
This press release contains forward-looking information, including statements about the impact of new products on Genzyme's position in the surgical products market, the efficacy of Seprafilm and cardiomyocyte transplantation for cardiovascular indications, the start of clinical trials, and the market launch of transgenic ATIII.
We are pleased that this study appears to confirm the results of our phase I ATIII study in healthy individuals and extends its safety profile to CABG patients," said James A.
Genzyme General began funding transgenic ATIII during an option period that began on April 1, 1996.